Regeneron: Buy Rating Backed by Promising Pipeline and Market Expansion Potential

Akash Tewari, an analyst from Jefferies, maintained the Buy rating on Regeneron (REGN – Research Report). The associated price target was lowered to $804.00.

Akash Tewari has given his Buy rating due to a combination of factors influencing Regeneron’s market position and future prospects. Despite recent setbacks, such as the decline in stock value following the IL-33 trial failure in COPD, Tewari remains optimistic about Regeneron’s upcoming pivotal studies. The company is expected to release results from two significant studies this year, focusing on C5 in generalized myasthenia gravis and LAG3 in metastatic melanoma, both of which are anticipated to yield positive outcomes.
While there is skepticism about the differentiation of Regeneron’s LAG3 combination in melanoma compared to Bristol-Myers Squibb’s offering, the potential for Regeneron’s treatment to capture a portion of the metastatic melanoma market remains. Tewari’s analysis suggests that the current valuation of Regeneron may not fully reflect its pipeline potential, particularly when considering the company’s broader portfolio beyond its existing products like Eylea. This assessment underpins the Buy rating, highlighting the potential for future growth and market expansion.

Tewari covers the Healthcare sector, focusing on stocks such as Pfizer, BioNTech SE, and Argenx Se. According to TipRanks, Tewari has an average return of 4.2% and a 41.30% success rate on recommended stocks.

In another report released on June 2, Bernstein also maintained a Buy rating on the stock with a $750.00 price target.